526 related articles for article (PubMed ID: 25663062)
1. Optimized human factor IX expression cassettes for hepatic-directed gene therapy of hemophilia B.
Zhang R; Wang Q; Zhang L; Chen S
Front Med; 2015 Mar; 9(1):90-9. PubMed ID: 25663062
[TBL] [Abstract][Full Text] [Related]
2. Optimization of self-complementary AAV vectors for liver-directed expression results in sustained correction of hemophilia B at low vector dose.
Wu Z; Sun J; Zhang T; Yin C; Yin F; Van Dyke T; Samulski RJ; Monahan PE
Mol Ther; 2008 Feb; 16(2):280-9. PubMed ID: 18059373
[TBL] [Abstract][Full Text] [Related]
3. Gene therapy for hemophilia B mice with scAAV8-LP1-hFIX.
Lu W; Zhou Q; Yang H; Wang H; Gu Y; Shen Q; Xue J; Dong X; Chen J
Front Med; 2016 Jun; 10(2):212-8. PubMed ID: 27052253
[TBL] [Abstract][Full Text] [Related]
4. Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial.
Monahan PE; Sun J; Gui T; Hu G; Hannah WB; Wichlan DG; Wu Z; Grieger JC; Li C; Suwanmanee T; Stafford DW; Booth CJ; Samulski JJ; Kafri T; McPhee SW; Samulski RJ
Hum Gene Ther; 2015 Feb; 26(2):69-81. PubMed ID: 25419787
[TBL] [Abstract][Full Text] [Related]
5. Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins.
Nathwani AC; Rosales C; McIntosh J; Rastegarlari G; Nathwani D; Raj D; Nawathe S; Waddington SN; Bronson R; Jackson S; Donahue RE; High KA; Mingozzi F; Ng CY; Zhou J; Spence Y; McCarville MB; Valentine M; Allay J; Coleman J; Sleep S; Gray JT; Nienhuis AW; Davidoff AM
Mol Ther; 2011 May; 19(5):876-85. PubMed ID: 21245849
[TBL] [Abstract][Full Text] [Related]
6. Stable human FIX expression after 0.9G intrauterine gene transfer of self-complementary adeno-associated viral vector 5 and 8 in macaques.
Mattar CN; Nathwani AC; Waddington SN; Dighe N; Kaeppel C; Nowrouzi A; Mcintosh J; Johana NB; Ogden B; Fisk NM; Davidoff AM; David A; Peebles D; Valentine MB; Appelt JU; von Kalle C; Schmidt M; Biswas A; Choolani M; Chan JK
Mol Ther; 2011 Nov; 19(11):1950-60. PubMed ID: 21629224
[TBL] [Abstract][Full Text] [Related]
7. Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver.
Nathwani AC; Gray JT; Ng CY; Zhou J; Spence Y; Waddington SN; Tuddenham EG; Kemball-Cook G; McIntosh J; Boon-Spijker M; Mertens K; Davidoff AM
Blood; 2006 Apr; 107(7):2653-61. PubMed ID: 16322469
[TBL] [Abstract][Full Text] [Related]
8. Hemophilia Gene Therapy: Ready for Prime Time?
VandenDriessche T; Chuah MK
Hum Gene Ther; 2017 Nov; 28(11):1013-1023. PubMed ID: 28793786
[TBL] [Abstract][Full Text] [Related]
9. Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates.
Nathwani AC; Gray JT; McIntosh J; Ng CY; Zhou J; Spence Y; Cochrane M; Gray E; Tuddenham EG; Davidoff AM
Blood; 2007 Feb; 109(4):1414-21. PubMed ID: 17090654
[TBL] [Abstract][Full Text] [Related]
10. Development of a Clinical Candidate AAV3 Vector for Gene Therapy of Hemophilia B.
Brown HC; Doering CB; Herzog RW; Ling C; Markusic DM; Spencer HT; Srivastava A; Srivastava A
Hum Gene Ther; 2020 Oct; 31(19-20):1114-1123. PubMed ID: 32657150
[TBL] [Abstract][Full Text] [Related]
11. Intravenous administration of an AAV-2 vector for the expression of factor IX in mice and a dog model of hemophilia B.
Harding TC; Koprivnikar KE; Tu GH; Zayek N; Lew S; Subramanian A; Sivakumaran A; Frey D; Ho K; VanRoey MJ; Nichols TC; Bellinger DA; Yendluri S; Waugh J; McArthur J; Veres G; Donahue BA
Gene Ther; 2004 Jan; 11(2):204-13. PubMed ID: 14712305
[TBL] [Abstract][Full Text] [Related]
12. Gene therapy for hemophilia B using CB 2679d-GT: a novel factor IX variant with higher potency than factor IX Padua.
Nair N; De Wolf D; Nguyen PA; Pham QH; Samara-Kuko E; Landau J; Blouse GE; Chuah MK; VandenDriessche T
Blood; 2021 May; 137(21):2902-2906. PubMed ID: 33735915
[TBL] [Abstract][Full Text] [Related]
13. The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle gene therapy.
Finn JD; Nichols TC; Svoronos N; Merricks EP; Bellenger DA; Zhou S; Simioni P; High KA; Arruda VR
Blood; 2012 Nov; 120(23):4521-3. PubMed ID: 22919027
[TBL] [Abstract][Full Text] [Related]
14. Efficient induction of immune tolerance to coagulation factor IX following direct intramuscular gene transfer.
Cohn EF; Zhuo J; Kelly ME; Chao HJ
J Thromb Haemost; 2007 Jun; 5(6):1227-36. PubMed ID: 17362228
[TBL] [Abstract][Full Text] [Related]
15. What´s new in Gene Therapy of Hemophilia.
Rodriguez-Merchan EC
Curr Gene Ther; 2018; 18(2):107-114. PubMed ID: 29446741
[TBL] [Abstract][Full Text] [Related]
16. Potential limits of AAV-based gene therapy with the use of new transgenes expressing factor IX fusion proteins.
Le Quellec S; Dane A; Enjolras N; McIntosh J; Rosales C; Negrier C; Nathwani A
Haemophilia; 2019 Jan; 25(1):e11-e18. PubMed ID: 30520547
[TBL] [Abstract][Full Text] [Related]
17. Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant.
George LA; Sullivan SK; Giermasz A; Rasko JEJ; Samelson-Jones BJ; Ducore J; Cuker A; Sullivan LM; Majumdar S; Teitel J; McGuinn CE; Ragni MV; Luk AY; Hui D; Wright JF; Chen Y; Liu Y; Wachtel K; Winters A; Tiefenbacher S; Arruda VR; van der Loo JCM; Zelenaia O; Takefman D; Carr ME; Couto LB; Anguela XM; High KA
N Engl J Med; 2017 Dec; 377(23):2215-2227. PubMed ID: 29211678
[TBL] [Abstract][Full Text] [Related]
18. Hyperactivity of factor IX Padua (R338L) depends on factor VIIIa cofactor activity.
Samelson-Jones BJ; Finn JD; George LA; Camire RM; Arruda VR
JCI Insight; 2019 Jun; 5(14):. PubMed ID: 31219805
[TBL] [Abstract][Full Text] [Related]
19. Recombinant Adeno-Associated Viral Vectors Expressing Human Coagulation FIX-E456H Variant in Hemophilia B Mice.
Le Quellec S; Dane AP; Barbon E; Bordet JC; Mingozzi F; Dargaud Y; Marais T; Biferi MG; Négrier C; Nathawani AC; Enjolras N
Thromb Haemost; 2019 Dec; 119(12):1956-1967. PubMed ID: 31659733
[TBL] [Abstract][Full Text] [Related]
20. New and improved AAVenues: current status of hemophilia B gene therapy.
Brimble MA; Reiss UM; Nathwani AC; Davidoff AM
Expert Opin Biol Ther; 2016; 16(1):79-92. PubMed ID: 26524468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
